Abstract
High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have